久之洋 reported revenue of ¥0.20B for the period ended 2026-06-30, +0.1% year on year. Net income was ¥0.01B, a 7.0% net margin on a 21.9% gross margin. The largest revenue line is 红外、激光等产品的制造与销售 at 98% of the total. Free cash flow for the period was ¥0.19B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.20B | +0.1% |
| Gross profit | ¥0.04B | — |
| Operating income | ¥0.01B | — |
| Net income | ¥0.01B | +46.0% |
| Gross margin | 21.9% | Net margin 7.0% |
| Revenue Q/Q | +211.3% | — |
| Segment | Revenue | Share |
|---|---|---|
| 红外、激光等产品的制造与销售 | ¥0.19B | 97.6% |
| 其他(补充) | ¥0.00B | 2.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.15B | 78.1% |
| R&D | ¥0.03B | 17.2% |
| SG&A | ¥0.03B | 13.0% |
| Tax & other | ¥-0.00B | -1.6% |
| Item | Amount |
|---|---|
| Total assets | ¥1.83B |
| Total liabilities | ¥0.52B |
| Shareholders' equity | ¥1.31B |
| Equity / assets | 71.5% |
| Operating cash flow | ¥0.19B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥0.19B |
| Cash conversion (OCF / net income) | 1592% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
海波重科 ・ 新迅达 ・ 新光药业 ・ 科大国创 ・ 爱司凯 ・ 世名科技 ・ 辰安科技 ・ 博思软件 ・ ST应急 ・ 幸福蓝海 ・ 健帆生物 ・ 领湃科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies